Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
for tags : Therapeutics save search
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
Published: 2024-04-24 (Crawled : 20:00) - globenewswire.com
ACRV | $9.46 -3.67% -3.81% 300K
|
| Email alert
Add to watchlist
acr-368 positive pipeline for program therapeutics today
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2024-04-24 (Crawled : 17:00) - globenewswire.com
SWTX | $43.37 -1.43% -1.45% 470K
|
Health Technology
|
| O: -0.05%
H: 2.16%
C: -1.36%
presentation for meeting therapeutics
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
Published: 2024-04-24 (Crawled : 14:00) - globenewswire.com
BTAI | News | $2.7 -9.09% -10.0% 880K
|
Health Technology
|
| O: 0.0%
H: 0.67%
C: -8.75%
bxcl701 keytruda presentation asco pancreatic for meeting trial therapeutics
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2024-04-24 (Crawled : 14:00) - globenewswire.com
HOWL | $6.405 -0.54% -0.55% 82K
|
Professional, Scientific, and T...
|
| O: -0.93%
H: 4.23%
C: 0.16%
wtx-124 presentation for meeting therapeutics
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
Published: 2024-04-24 (Crawled : 13:00) - globenewswire.com
CAPR | $5.04 4.56% 4.37% 910K
|
Health Technology
|
| O: 9.13%
H: 7.41%
C: -4.18%
cap-1002 fda positive program therapeutics duchenne type-b meeting
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Published: 2024-04-24 (Crawled : 13:00) - globenewswire.com
GANX | $3.16 -6.78% -7.28% 150K
|
Professional, Scientific, and T...
|
| O: 4.42%
H: 3.11%
C: -9.89%
gt-0228 disease positive for parkinson’s trial therapeutics therapy results
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Published: 2024-04-24 (Crawled : 11:00) - globenewswire.com
TVTX | $5.46 -4.88% -5.13% 2M
|
Health Technology
|
| O: -2.2%
H: 0.0%
C: -5.71%
filspari nephropathy treatment for therapeutics
Xaira Therapeutics Launches to Deliver Transformative Medicines by Advancing and Harnessing AI for Drug Discovery and Development
Published: 2024-04-24 (Crawled : 08:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -1.02%
H: 0.0%
C: 0.0%
drug for therapeutics development
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Published: 2024-04-24 (Crawled : 07:00) - prnewswire.com
AKBA | $1.36 -0.73% -0.74% 1.5M
|
Health Technology
|
| O: 0.0%
H: 2.19%
C: 0.0%
TVTX | $5.46 -4.88% -5.13% 2M
|
Health Technology
|
| O: -2.2%
H: 0.0%
C: -5.71%
filspari nephropathy treatment for therapeutics
Curio Digital Therapeutics Inc. Announces the U.S. Food and Drug Administration (FDA) Clearance of MamaLift Plus™, the First Prescription Digital Therapeutic Authorized for the Treatment of Postpartum Depression (PPD)
Published: 2024-04-23 (Crawled : 00:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.7%
H: 0.0%
C: 0.0%
first drug authorized food depression treatment clearance for therapeutics
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
HOWL | $6.405 -0.54% -0.55% 82K
|
Professional, Scientific, and T...
|
| O: 2.17%
H: 5.06%
C: 5.06%
il-10 first disease preclinical for meeting therapeutics potential therapy
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
Published: 2024-04-23 (Crawled : 05:00) - prnewswire.com
VRTX | $400.66 -1.05% -1.06% 810K
|
Health Technology
|
| O: 1.62%
H: 0.71%
C: 0.23%
cell for collaboration therapeutics diabetes agreement
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
Published: 2024-04-22 (Crawled : 20:00) - globenewswire.com
FATE | News | $4.3 -5.29% -5.58% 2M
|
Health Technology
|
| O: 0.21%
H: 4.8%
C: -5.22%
ft819 presentation for meeting therapeutics
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025Trial's lower-than-expected event rate suggests improved survival outcomes
Published: 2024-04-22 (Crawled : 13:00) - biospace.com/
PBLA | News | $0.42 -6.31% 64K
|
Professional, Scientific, and T...
|
| O: -4.76%
H: 17.5%
C: 17.5%
aspire for trial therapeutics
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
Published: 2024-04-22 (Crawled : 12:00) - globenewswire.com
CGTX | News | $2.0 0.0% 110K
|
|
| O: -2.17%
H: 7.78%
C: 3.33%
disease alzheimer’s treat for therapeutics platform
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
Published: 2024-04-22 (Crawled : 12:00) - globenewswire.com
LXEO | News | $12.445 2.51% 2.45% 99K
|
|
| O: 3.42%
H: 5.56%
C: 2.01%
lx2006 license treatment for therapeutics agreement development
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential
Published: 2024-04-22 (Crawled : 11:00) - globenewswire.com
BTAI | News | $2.7 -9.09% -10.0% 880K
|
Health Technology
|
| O: 5.2%
H: 4.76%
C: 4.4%
bxcl501 for therapeutics potential market
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
Published: 2024-04-18 (Crawled : 12:00) - globenewswire.com
TGTX | $13.99 -1.83% -1.86% 2.7M
|
Health Technology
|
| O: -0.43%
H: 4.57%
C: 0.0%
briumvi neurology sclerosis for meeting therapeutics
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
CERE | $41.87 -0.29% -0.29% 630K
|
Finance
|
| O: 0.78%
H: 0.0%
C: 0.0%
disease positive for topline parkinson’s trial therapeutics results living
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
TGTX | $13.99 -1.83% -1.86% 2.7M
|
Health Technology
|
| O: -0.43%
H: 4.57%
C: 0.0%
cd20 briumvi contract sclerosis for therapeutics
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.